UNLABELLED: Although the vasculogenic potential of circulating and cord blood (CB)-derived endothelial colony-forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Here we used a fetal sheep model of in utero transplantation to investigate and compare the intrinsic ability of human CB-derived ECFC to migrate to the liver and to the intestine, and to define ECFC's intrinsic ability to integrate and contribute to the cytoarchitecture of these same organs. ECFCs were transplanted by an intraperitoneal or intrahepatic route (IH) into fetal sheep at concentrations ranging from 1.1-2.6 × 10(6) cells/fetus. Recipients were evaluated at 85 days posttransplant for donor (human) cells using flow cytometry and confocal microscopy. We found that, regardless of the route of injection, and despite the IH delivery of ECFC, the overall liver engraftment was low, but a significant percentage of cells were located in the perivascular regions and retained the expression of hallmark endothelial makers. By contrast, ECFC migrated preferentially to the intestinal crypt region and contributed significantly to the myofibroblast population. Furthermore, ECFC expressing CD133 and CD117 lodged in areas where endogenous cells expressed those same phenotypes. CONCLUSION: ECFC inherently constitute a potential source of cells for the treatment of intestinal diseases, but strategies to increase the numbers of ECFC persisting within the hepatic parenchyma are needed in order to enhance ECFC therapeutic potential for this organ.
UNLABELLED: Although the vasculogenic potential of circulating and cord blood (CB)-derived endothelial colony-forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Here we used a fetal sheep model of in utero transplantation to investigate and compare the intrinsic ability of human CB-derived ECFC to migrate to the liver and to the intestine, and to define ECFC's intrinsic ability to integrate and contribute to the cytoarchitecture of these same organs. ECFCs were transplanted by an intraperitoneal or intrahepatic route (IH) into fetal sheep at concentrations ranging from 1.1-2.6 × 10(6) cells/fetus. Recipients were evaluated at 85 days posttransplant for donor (human) cells using flow cytometry and confocal microscopy. We found that, regardless of the route of injection, and despite the IH delivery of ECFC, the overall liver engraftment was low, but a significant percentage of cells were located in the perivascular regions and retained the expression of hallmark endothelial makers. By contrast, ECFC migrated preferentially to the intestinal crypt region and contributed significantly to the myofibroblast population. Furthermore, ECFC expressing CD133 and CD117 lodged in areas where endogenous cells expressed those same phenotypes. CONCLUSION: ECFC inherently constitute a potential source of cells for the treatment of intestinal diseases, but strategies to increase the numbers of ECFC persisting within the hepatic parenchyma are needed in order to enhance ECFC therapeutic potential for this organ.
Authors: Patrick Au; Laurence M Daheron; Dan G Duda; Kenneth S Cohen; James A Tyrrell; Ryan M Lanning; Dai Fukumura; David T Scadden; Rakesh K Jain Journal: Blood Date: 2007-11-09 Impact factor: 22.113
Authors: Andrea Garolla; Renata D'Incà; Davide Checchin; Andrea Biagioli; Luca De Toni; Valentina Nicoletti; Marco Scarpa; Elisa Bolzonello; Giacomo Carlo Sturniolo; Carlo Foresta Journal: Am J Gastroenterol Date: 2009-06-30 Impact factor: 10.864
Authors: R K Burt; A Testori; Y Oyama; H E Rodriguez; K Yaung; M Villa; J M Bucha; F Milanetti; J Sheehan; N Rajamannan; W H Pearce Journal: Bone Marrow Transplant Date: 2009-05-18 Impact factor: 5.483
Authors: Evan J Colletti; Judith A Airey; Wansheng Liu; Paul J Simmons; Esmail D Zanjani; Christopher D Porada; Graça Almeida-Porada Journal: Stem Cell Res Date: 2008-09-16 Impact factor: 2.020
Authors: Flavio G Rocha; Cathryn A Sundback; Nicholas J Krebs; J Kent Leach; David J Mooney; Stanley W Ashley; Joseph P Vacanti; Edward E Whang Journal: Biomaterials Date: 2008-04-08 Impact factor: 12.479
Authors: Van Anh Nguyen; Christina Fürhapter; Petra Obexer; Hella Stössel; Nikolaus Romani; Norbert Sepp Journal: J Cell Mol Med Date: 2009-03 Impact factor: 5.310
Authors: Christopher Stem; Christopher Rodman; Ritu M Ramamurthy; Sunil George; Diane Meares; Andrew Farland; Anthony Atala; Christopher B Doering; H Trent Spencer; Christopher D Porada; Graça Almeida-Porada Journal: Front Cell Dev Biol Date: 2021-08-10
Authors: Cheen P Khoo; Maria G Roubelakis; Jack B Schrader; Grigorios Tsaknakis; Rebecca Konietzny; Benedikt Kessler; Adrian L Harris; Suzanne M Watt Journal: Sci Rep Date: 2017-03-09 Impact factor: 4.379